Search

A novel human homologue of Escherichia coli, yeast and plant 1-acylglycerol-3-phosphate acyltransferase has been isolated from U937 cell cDNA. Expression of the cloned sequence in 1-acylglycerol-3-phosphate acyltransferase-deficient E. coli resulted in increased incorporation of oleic acid into cellular phospholipids. Membranes made from COS7 cells transfected with the cDNA exhibited higher acyltransferase activity towards a range of donor fatty acyl-CoAs and lysophosphatidic acid. Northern-blot analysis of the cDNA sequence indicated high levels of expression in immune cells and epithelium. Rapid amplification of cDNA ends revealed differentially expressed splice variants, which suggests regulation of the enzyme by alternative splicing. This cDNA therefore represents the first described sequence of a mammalian gene homologous to non-mammalian lysophosphatidic acid acyltransferases.

Comparative two-dimensional proteome analysis was used to identify proteins differentially expressed in multiple clinical normal and breast cancer tissues. One protein, the expression of which was elevated in invasive ductal and lobular breast carcinomas when compared with normal breast tissue, was arylamine N-acetyltransferase-1 (NAT-1), a Phase II drug-metabolizing enzyme. NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors. Analysis of the effect of active NAT-1 overexpression in a normal luminal epithelial-derived cell line demonstrated enhanced growth properties and etoposide resistance relative to control cells. Thus, NAT-1 may not only play a role in the development of cancers through enhanced mutagenesis but may also contribute to the resistance of some cancers to cytotoxic drugs.

cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984,44,5427-5431. 51. Hansson J, Berhane K, Castro VM, Jungnelius U, Mannervik B, Ringborg U. Sensitization of human melanoma cells to the cytotoxic effects of melphalan by the glutathione transferase inhibitor e-&crynic acid. CancerRes 1991,51,94-98. 52. Lee SM, Thatcher N, Ma&son GP. OQlkylguanine-DNA alkylrransferase depletion and regeneration in human peripheral lymphocvtes followina dacarbazine and fotemustine. Cancer Res 1991,51, 6i9-623. 53. Gerson SL, Trey JE. Modulation of nitrosourea resistance in mveloid leukemias. Blood 1988,71,1487-1494. 54. $&men LJ, Barnes DM, Fish& SG, Albain KS, Fisher RI, Erickson LC. l-/3-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(I1) and modification of platinum-DNA interstrand crossliig. Cancer Res 1989,49,1383-1389. 55. Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. C&cer Res 1991,51,51&513. 56. Poon MA, O’Connell MJ, Moertel CG, et al. Biochemical modu